Amir Reza Jalilian - Radiopharmaceutical Research and Development Laboratory, Nuclear Science and Technology Research Institute, Atomic Energy organization of Iran, Tehran, Iran
Hassan Yousefnia - Radiopharmaceutical Research and Development Laboratory, Nuclear Science and Technology Research Institute, Atomic Energy organization of Iran, Tehran, Iran
Mohsen Kamali-Dehghan - Agricultural, Medical and Industrial research School, Nuclear Science and Technology Research Institute, Atomic Energy organization of Iran, Karaj, Iran
Sedigheh Moradkhani - Agricultural, Medical and Industrial research School, Nuclear Science and Technology Research Institute, Atomic Energy organization of Iran, Karaj, Iran

  Introduction: [61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu]ATSM) is a well-established hypoxia imaging tracer with simple production and significant specifity. In this work the accumulation of the tracer is studied in wild-type, necrotic and hypoxic fibrosarcoma tumors. Methods: [61Cu]ATSM was prepared using ATSM ligand and [61Cu]CuOAc followed by i.v. administration and imaging studies in wild-type rats and hypoxic fibrosarcoma-bearing mice. Results: [61Cu]ATSM with high radiochemical purity (> 99%, HPLC, RTLC) was injected to wild-type rats as well as hypoxic and necrotic fibrosarcoma-bearing mice followed by imaging up to 3 hours. Conclusion: [61Cu]ATSM was mainly accumulated in liver, as well as kidney and bladder and less but still significant in brain of wild-type rats. A significant and hypoxia-specific tumor/non tumor ratio in hypoxic models was observed by co-incidence imaging 2 h post injection, while in necrotic and 12-week tumor-induced mice very slight tumor uptakes were detected. [61Cu]ATSM is a positron emission tomography (PET) radiotracer for selective tumor hypoxia imaging from necrotic and proliferative tumors.

[61Cu]ATSM, Copper radiopharmaceuticals, Hypoxia, Co-incidence imaging, Fibrosarcoma